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Glycogen synthase kinase-3 (GSK-3) plays a critical role in cognitive dysfunction
associated with Alzheimer’s disease (AD), yet the mechanism by which GSK-3 alters
cognitive processes in other disorders, such as schizophrenia, remains unknown.
In the present study, we demonstrated a role for GSK-3 in the direct regulation of
neuronal oscillations in hippocampus (HIP) and prelimbic cortex (PL). A comparison
of the GSK-3 inhibitors SB 216763 and lithium demonstrated disparate effects of the
drugs on spatial memory and neural oscillatory activity in HIP and PL. SB 216763
administration improved spatial memory whereas lithium treatment had no effect.
Analysis of neuronal local field potentials in anesthetized animals revealed that whereas
both repeated SB 216763 (2.5 mg/kg) and lithium (100 mg/kg) induced a theta
frequency spike in HIP at approximately 10 Hz, only SB 216763 treatment induced
an overall increase in theta power (4–12 Hz) compared to vehicle. Acute administration
of either drug suppressed slow (32–59 Hz) and fast (61–100 Hz) gamma power. In PL,
both drugs induced an increase in theta power. Repeated SB 216763 increased HIP–PL
coherence across all frequencies except delta, whereas lithium selectively suppressed
delta coherence. These findings demonstrate that GSK-3 plays a direct role in the
regulation of theta oscillations in regions critically involved in cognition, and highlight
a potential mechanism by which GSK-3 may contribute to cognitive decline in disorders
of cognitive dysfunction.
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INTRODUCTION
Glycogen synthase kinase-3 (GSK-3) is a constitutively active protein kinase with an array of
physiological functions including mediating intracellular signaling, as well as regulating neuronal
plasticity, gene expression, and cell survival (Grimes and Jope, 2001). GSK-3 exists as two isoforms,
GSK-3α and GSK-3β, but the major research focus has been on GSK-3β as a result of its
involvement in neuropsychiatric and neurodegenerative disease. Indeed, in recent years GSK-3
has been shown to be fundamental to the processes underlying cognitive function and evidence
suggests that increased GSK-3 activity may represent a common biochemical mediator of impaired
cognitive function in many central nervous system diseases (Emamian et al., 2004; Takashima,
2006; Ances et al., 2008; King et al., 2013).
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A role for overactive GSK-3 as a critical mediator of
cognitive decline in Alzheimer’s disease (AD) has been widely
documented (Balaraman et al., 2006; Huang and Klein, 2006;
Martinez and Perez, 2008; Muyllaert et al., 2008; Medina and
Avila, 2010; Maqbool et al., 2016). In AD, overactivation of
GSK-3 induces hyperphosphorylation of tau proteins resulting
in the development of neurofibrillary tangles (NFTs) (Balaraman
et al., 2006; Llorens-Martin et al., 2014) which are thought to
contribute directly to cognitive dysfunction (Bloom, 2014). In
schizophrenia, a disorder associated with cognitive dysfunction,
a role for elevated GSK-3 activity in the neuropathology
of this disorder is provided by postmortem findings, as
well as genetic and behavioral studies. For example, reduced
phosphorylation levels of GSK-3 (which correlate with increased
activity) in postmortem frontal cortex samples of patients with
schizophrenia has been documented (Emamian et al., 2004). In
addition, associations between genetic variation in the GSK-3
gene and schizophrenia (SZ) have been reported (Li et al., 2011;
Blasi et al., 2013; Tang et al., 2013) and a number of other
susceptibility genes for SZ, including the genes encoding for
the proteins disrupted in SZ (DISC1), neuregulin 1 (NRG-1),
and dysbindin converge on GSK-3 signaling (Numakawa et al.,
2004; Clapcote et al., 2007; Keri et al., 2009; Mao et al., 2009;
Guo et al., 2010; Seres et al., 2010; Lipina et al., 2011, 2012).
More recently, developmental inhibition of GSK-3 was shown
to alleviate spatial memory deficiencies in a mouse model of
schizophrenia predisposition (Tamura et al., 2016) indicative of
a direct link between GSK-3 and the development of processes
critical to aberrant cognitive functioning in this disorder. In
line with these findings GSK-3 has been shown to be involved
in mediating reductions in cognitive performance associated
with diabetes mellitus (King et al., 2013; Wang and Zhao,
2016), Fragile-X syndrome (Guo et al., 2012; Franklin et al.,
2014; Pardo et al., 2017), and human immunodeficiency virus
(Ances et al., 2008), and in a model of traumatic brain injury
improvements in spatial memory induced by valproate were
associated with inhibition of GSK-3 in hippocampus (Dash et al.,
2010).
A critical role for GSK-3 in inducing cognitive dysfunction
via neurofibrillary tangle formation in AD is known. Yet, the
involvement of this protein in other disorders of cognitive decline
raises the possibility of an additional, and more direct, role
for this kinase in mediating the processes underlying learning
and memory not only in disease, but in healthy organisms
as well. This idea is supported by studies in healthy animals
showing that increased GSK-3 expression, within whole brain
or in cortical and hippocampal neurons, could negatively affect
cognitive function in both rats and mice (Hernandez et al.,
2002; Liu et al., 2003). However, behavioral studies examining
the effects of GSK-3 inhibitors on learning and memory
under normal conditions are conflicting, with some reports
showing positive (Nocjar et al., 2007; Lipina et al., 2013),
negative (Al Banchaabouchi et al., 2004; Hu et al., 2009), or
no effects of the drugs (Guo et al., 2012; Franklin et al., 2014).
Despite these disparate findings, the large number of studies
showing a role for GSK-3 in mediating cognitive performance
in neurodegenerative disease, neuropsychiatric disorders and
in injury, suggest that while a number of neuropathological
processes may converge on GSK-3 signaling, the downstream
effects of its increased activation are likely similar across many
disease processes.
One possible consequence of increased GSK-3 activation
is through the disruption of brain electrophysiological
rhythms. Neuronal oscillatory rhythms, which are derived
from macroscopic oscillations of neuronal populations, have
patterns that are highly conserved across species (Buzsaki
et al., 2013) and are critical to cognitive functioning (Igarashi,
2015; Helfrich and Knight, 2016). Neuronal oscillations in
prefrontal cortex (PFC) and hippocampus (HIP) specifically
have been shown to be of significant importance, having been
linked with working memory in both humans (Cohen, 2011;
Roux and Uhlhaas, 2014) and in animals (Pesaran et al., 2002;
Benchenane et al., 2010; O’Neill et al., 2013), and dysregulated
neuronal oscillatory activity in and between HIP and PFC
have been widely documented in disease states such as AD and
schizophrenia (Kwon et al., 1999; Herrmann and Demiralp,
2005; Schmiedt et al., 2005; Basar-Eroglu et al., 2007; Uhlhaas
et al., 2008; Missonnier et al., 2010; Uhlhaas and Singer, 2010;
Basar et al., 2013, 2016). For example, in humans or animal
models reduced event-related increases in cortical gamma
activity, or gamma-theta frequency coupling, in both AD and
schizophrenia have been demonstrated (Kwon et al., 1999;
Basar-Eroglu et al., 2007; Lodge et al., 2009; Missonnier et al.,
2010; Zhang et al., 2016; Nakazono et al., 2017). Additionally in
HIP, rodent models have demonstrated reduced elicited theta
power, and/or gamma-theta coupling, in both disorders (Howlett
et al., 2004; Villette et al., 2010; Scott et al., 2012; Mesbah-Oskui
et al., 2015; Kalweit et al., 2017), with the augmentation of
elicited theta power demonstrated to be characteristic of drugs
used in clinical treatment of AD such as acetylcholinesterase
inhibitors and memantine (Kinney et al., 1999; Guadagna et al.,
2012).
Further evidence of a role for GSK-3 in neuronal oscillations
comes from reports showing the regulation of ion channel
function by this protein kinase (Wildburger and Laezza, 2012).
Of relevance to the proposed study, GSK-3 has been shown
to control the function of the N-methyl-D-aspartate (NMDA)
receptor (Chen et al., 2007), a receptor also implicated in
the regulation of oscillatory activity within the PFC and
HIP (Lee et al., 2017; Lemercier et al., 2017; Miller et al.,
2017). Specifically, Chen et al. (2007) demonstrated that the
pharmacological inhibition or silencing of GSK-3 induced
a long-lasting reduction of NMDA receptor-mediated ionic
synaptic current in cortical pyramidal neurons. Interestingly,
the effect of GSK-3 was specific for the GluN2B-containing
NMDA receptors (Chen et al., 2007), receptors that are involved
in the induction of long-term depression (LTD) (Liu et al.,
2004; Massey et al., 2004). In addition to regulating NMDA
receptor function, GSK-3 is also involved in voltage-gated
sodium (Nav) channel function, both through regulation of
surface expression (Yanagita et al., 2009; James et al., 2015)
or functional activity via phosphorylation of fibroblast growth
factor 14 (FGF14) (Shavkunov et al., 2013), a protein that
interacts with the C terminus of Nav channels to regulate
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both the functional properties and subcellular distribution of
the channels (Goldfarb et al., 2007; Shavkunov et al., 2013).
Nav channels have been recently shown to play a role in the
regulation of PFC and HIP gamma oscillations (Verret et al.,
2012; Rama et al., 2015), and have been implicated as playing
a key role in the neuropathophysiology of AD (Verret et al.,
2012).
Lithium has been shown to inhibit GSK-3β directly in vitro,
albeit with high Ki (∼2.0 for GSK-3β, Klein and Melton), and
in vivo through activation of Akt (Beaulieu et al., 2004). However,
lithium has also been demonstrated to inhibit other enzymes
including inositol monophosphatases (IMPAs) (Berridge et al.,
1989), bisphosphate 3′-nucleotidase (BPNT1) (Spiegelberg et al.,
2005), and cyclooxygenase (COX) (Klein and Melton, 1996;
Stambolic et al., 1996). Furthermore, lithium has been shown
to influence numerous neurotransmitter systems including,
serotonin, dopamine, and glutamate (Malhi et al., 2013). Despite
the known role of GSK-3 in learning and memory, the effects
of lithium on cognition are conflicting, with studies showing
positive effects (Letendre et al., 2006; Nunes et al., 2013;
Matsunaga et al., 2015; Daglas et al., 2016; Forlenza et al.,
2016), little to no effect (Joffe et al., 1988; Schifitto et al.,
2009; Bourne et al., 2013; Pfennig et al., 2014; Decloedt et al.,
2016), or negative effects (Shaw et al., 1987; Monks et al., 2004;
Senturk et al., 2007) of treatment on cognitive function. In the
present study, we therefore sought to evaluate and compare
the effects of a direct GSK-3 inhibitor, SB 216763, with lithium
on the regulation of neuronal oscillatory activity within, and
between, the HIP and PFC and the impact of these drugs on
cognitive performance in a water maze test of spatial memory
and reversal learning, tests that require HIP and PFC function,
respectively (Broersen, 2000; Graybeal et al., 2011). Animals were
administered five daily drug or vehicle injections with recordings
taken from anesthetized rats at baseline, prior to behavioral




Twenty-four adult male Wistar rats weighing approximately 350–
400 g at the start of the experiments were used. Rats were housed
up to three rats per cage in polyethylene cages in a colony room
maintained on a 12-h light–dark cycle with free access to food
and water. Rats were handled for 2 min daily for 5 days before
the start of experiments. All treatments were performed during
the light phase of the day–night cycle. All procedures involving
animals complied with the guidelines described in the Guide to
the Care and Use of Experimental Animals (Canadian Council
on Animal Care, 1993), and were approved by the Animal Care
Ethics Committee of the University of Toronto.
Drugs
The GSK-3 inhibitor SB 216763 (Tocris Bioscience) was dissolved
in a solution of DMSO, polyethylene glycol and sterile water,
and administered at a dose of 2.5 mg/kg (i.p.) (Zhao et al., 2016;
Wickens et al., 2017). Lithium chloride (lithium) was dissolved
in 0.9% saline and administered at a dose of 100 mg/kg (i.p.).
This dose was chosen as it was shown to increase phosphorylation
of Akt (Zheng et al., 2013), an upstream negative regulator of
GSK-3. For non-drug injections, an equivalent volume of vehicle
(50% of the control animals received saline and 50% received
DMSO, polyethylene glycol, sterile water) was administered. All
injections were administered at a volume of 1.0 ml/kg.
Behavior
Behavioral tests took place 10 min post-injection for SB 216763
and 30 min post-injection for lithium. Vehicle-treated animals
were divided into two groups that underwent testing 10 or
30 min post-injection. For this group the data was pooled as
no intra-group variation was evident. Animals were trained to
locate a submerged platform in the Morris water maze using
an allocentric task (i.e., using distal cues to find the platform)
(Broersen, 2000). The maze consisted of a circular pool (2 m
diameter) filled with water maintained at 23 ± 1◦C. The pool
contained a transparent circular platform (10 cm diameter) in
one quadrant with the surface 3 cm below the water surface, and
placed approximately 20 cm from the wall.
The allocentric task consisted of four trials per day with
an inter-trial interval of 2 min for four consecutive days.
Each trial began with placing the rat into the pool in one
of the three quadrants that did not contain the platform (the
starting quadrant was similar for all rats tested). Rats were
allowed to swim for 2 min after which, if the rat did not
find the platform, it was placed on the platform where it
remained for a period of 30 s. For each subsequent trial the
release point of the rat was shifted, however, the platform
always remained in the same position. During the reversal,
on day 5, the platform was moved to the quadrant opposite,
and animals were allocated up to 15 trials to locate the
platform under 20 s three times consecutively. Swimming
trajectories were recorded and analyzed with Any-maze software
(Stoelting). The escape latencies and distance traveled were
obtained from each rat. The mean swimming distance and
the mean daily latencies from the four daily trials were
compared.
Surgeries
Rats were anesthetized with isoflurane (induction 5%,
maintenance 2%), administered the analgesic ketoprofen
(5 mg/kg, s.c.) and secured in a stereotaxic frame. Body
temperature was maintained at 37◦C by a warming pad. Two
custom length (25 mm) polyimide-insulated stainless steel wire
twisted electrodes (Plastics One: E363/3-2TW, 0.125 mm) were
implanted unilaterally into the dorsal CA1 region of the HIP
(AP −3.6, ML −1.8, DV −2.9) and two into the prelimbic (PL)
region of the PFC (AP +3.0, L −0.7, DV −4.0; Paxinos and
Watson, 2005). Two screws attached to Teflon-insulated 20 mm
length stainless steel wire (Plastics One, E363/20, 0.56 mm) were
fixed into the skull above lambda as ground and the opposite
hemisphere from electrode placement as reference. Additional
anchor screws were attached to the skull and electrodes secured
with dental cement to the anchor screws. The animals received
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an additional injection of ketoprofen 24 h following surgery and
were allowed to recover individually in their home cage for a
minimum of 10 days before the experiments were performed.
Electrode placement was validated post-mortem.
Electrophysiology
All LFP oscillatory recordings (Intan Technologies) were
performed in anesthetized animals (isoflurane 2%) under
a heating lamp. Breathing and heart rate were monitored
while animals were under anesthesia. Baseline recordings were
performed 3 days prior to the beginning of the behavioral
experiment. During the behavioral experiment recordings were
taken post-drug injection following (and not prior to) the
last trial on Injection Day 1 (acute drug administration)
or Injection Day 5 (repeated drug administration). We
therefore chose to anesthetize the animals prior to recording
to evaluate drug-evoked responses and at the same time
eliminate the contribution of arousal state that may occur
as a result of variations in overall swimming duration.
LFP oscillatory data was collected for a 5 min period and
sampled at a rate of 5000 samples/s. The spectral power
of LFP oscillations in each region and coherence between
regions were analyzed using routines from the Chronux
software package for MATLAB (MathWorks). Recordings were
downsampled, segmented, detrended, and low-pass filtered to
remove high frequencies greater than 100 Hz. Continuous
multitaper spectral power and coherence (tapers = [5 9])
between regions was calculated for each segment in the following
frequency bands: delta (1–4 Hz), theta (>4–12 Hz), beta
(>12–32 Hz), slow gamma (>32–59 Hz), and fast gamma (>61–
100 Hz).
Data Analysis
For the behavioral data, trials were averaged and the statistical
significance of each dependent measure evaluated using a
repeated measures ANOVA with a within subjects factor of Trial
Day, and Drug as the between-subjects factors, and followed by
Bonferroni post hoc tests. All data are expressed as means± SEM.
LFP spectral power was normalized to total spectral power.
LFP power curves are reported as mean power for the slower
frequencies and log-transformed for the gamma frequencies
(>40 Hz) to better exhibit group differences. Quantification of
the LFP power data at each frequency measure is reported as
means ± SEM for between group comparisons, or as percent
change from baseline for within group comparisons. For the
within subjects analysis, a repeated measures ANOVA was
performed for each frequency, with a within subjects factor
of Injection # (baseline, 1 or 5 days), and followed by paired
Student’s t-tests for post hoc comparisons to baseline. Some
planned comparisons were performed to evaluate within subject
changes between acute or repeated drug treatments with baseline.
For the between subjects analysis, an ANOVA was performed
for each frequency at each Injection # (baseline, 1, 5 days),
with Drug as the between-subjects factor and followed by
Bonferroni post hoc comparisons. Computations were performed
using the SPSS/PC+ statistical package (IBM, Armonk, NY,
United States).
RESULTS
Effect of GSK-3 Inhibition on Spatial and
Reversal Learning
The experimental timeline is depicted in Figure 1A. To evaluate
whether GSK-3 inhibition could enhance spatial learning and
memory the effects of selective GSK-3 inhibitor SB 216763,
and the non-selective inhibitor lithium, on allocentric and
reversal learning in the Morris water maze were examined.
Significant differences between drug treatments in latency to
find the platform and the distance traveled in the maze
were evaluated. A comparison of all three groups across
injections revealed a significant Drug × Trial Day interaction
[F(6,60) = 2.5, p = 0.030]. SB 216763 resulted in improved
spatial learning such that by Injection 4 animals that received
SB 216763, but not lithium, exhibited a latency to escape
significantly faster than the vehicle-treated controls (SB vs.
Veh, p = 0.037, Bonferroni post hoc, Figure 1B) [Trial Day
4: Drug F(2,21) = 3.8, p = 0.041]. No significant differences
in the total swimming distance were observed between groups
(Figure 1C). Analysis of the swim trajectories revealed significant
Drug× Trial Day interactions when Center Time [F(6,60)= 2.3,
p = 0.038] and Center Distance [F(6,60) = 2.2, p = 0.04]
were analyzed. By Trial Day 4, SB 216763 treatment resulted
in the rats spending significantly more time in the center
of the pool (SB vs. Veh, p = 0.023, Bonferroni post hoc,
Figures 1D,E) which may reflect an anxiolytic effect of the drug
(Crofton et al., 2017).
To assess cognitive flexibility, which requires PFC function
(Graybeal et al., 2011), we next evaluated the animals
during a reversal learning task by shifting the platform
to the opposite quadrant and evaluating the number of
trials it took to learn the new location of the platform and
escape. No significant differences were evident between the
three treatment groups (Figure 1F). Across all trials, both
SB 216763- and lithium-treated animals spent a higher
proportion of time searching the center of the maze for
the platform during the reversal task (SB: 56.6 ± 2.6%,
lithium: 57.8 ± 3.1%, Veh: 42.7 ± 2.6%, Figure 1G)
[ANOVA: F(2,201) = 10.1, p = 0.0001]. Representative swim
trajectories for Injection 4 and the reversal task are displayed in
Figure 1H.
Temporal Effects of GSK-3 Inhibition on
HIP Oscillatory Activity
Before the first swim on trial day 1, and following the
final swim trial on days 1 and 5 LFP neuronal activity was
evaluated in anesthetized animals to assess temporal changes
in baseline, acute and repeated drug administration effects
on oscillatory activity and coherence in and between dorsal
HIP and PL (Figure 2A). LFPs are thought to represent the
summed synchronous activity of relatively large groups of
neurons (Mitzdorf, 1985; Logothetis, 2003), and can provide
vital information on synchronous network activity both within
and between regions. Evaluation of the oscillatory changes
in HIP and PL of vehicle-treated rats (Figures 2B,C) during
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FIGURE 1 | Effect of GSK-3 inhibition on learning and memory in the water
maze. (A) Experimental timeline. (B,C) SB 216763 (2.5 mg/kg, i.p.), but not
lithium (100 mg/kg, i.p.), reduced the latency to find the platform compared to
vehicle controls by Injection Day 4, with no significant effects on the total
distance traveled. (D,E) Rats treated with SB 216763 spent significantly more
time, and traveled greater distance, in the center of the maze whereas
vehicle-treated rats spent more time in the periphery. (F) There were no
differences between and treatments on the number of trials required to find
the platform during the reversal. (G) SB 216763 or lithium treatment resulted
in rats spending more time in the center of the maze compared to the
periphery during the reversal. (H) Representative swim plots from Injection 4
and the reversal test following drug treatment. N = 8 rats/group. Data are
expressed as means ± SEM. ∗p < 0.05, ∗∗p < 0.01, compared to
vehicle-treated rats, Bonferroni post hoc test.
water maze training revealed no significant within subject
Injection effects in HIP (Figures 2B,C). Recordings taken from
SB 216763-treated animals (Figures 2D,E) showed that, in
contrast to the vehicle-treated rats, SB 216763 treatment induced
significant changes in HIP theta oscillations as revealed by a
significant within subject effect of Injection [theta: F(2,22)= 4.6,
p = 0.023]. Repeated, but not acute, SB 216763 increased theta
power compared to baseline (p = 0.029, Figures 2D,E). There
were no significant Injection effects of lithium treatment and
planned comparisons to baseline revealed no significant effects
on overall theta power (Figures 2F,G), however, both repeated
SB 216763 or lithium administration induced a peak in the
theta band at approximately 10 Hz compared to baseline, an
effect also not evident in the vehicle-treated rats (Figure 2B).
Acute lithium treatment suppressed both slow (p = 0.029 vs.
baseline) and fast (p = 0.042 vs. baseline) gamma power in HIP,
however, these effects were lost with repeated drug treatment
(Figures 2F,G).
Temporal Effects of GSK-3 Inhibition on
PL Oscillatory Activity
Evaluation of drug effects in PL (Figure 3A) revealed no
Injection effects following vehicle treatment (Figures 3B,C).
Following SB 216763 administration an Injection effect was
evident for the slow gamma band [F(2,24) = 9.325, p = 0.0001],
with a reduction in slow gamma power following both acute
and repeated drug treatment (Figures 3D,E). Similar to that
observed in HIP, an increase in theta power was evident
following repeated SB 216763 treatment (p = 0.033 vs.
baseline). Animals treated with lithium exhibited significant
Injection effects in the delta, theta, beta, and fast gamma
bands [delta: F(2,30) = 7.6, p = 0.002; theta: F(2,30) = 9.4,
p = 0.001; beta: F(2,30) = 6.2, p = 0.006; fast gamma:
F(2,30) = 9.0, p = 0.001]. Compared to baseline acute lithium
increased delta power (p = 0.001), and suppressed theta
(p = 0.001), and slow gamma (p = 0.008) power, effects lost
with repeated treatment. Following 5 days of lithium treatment
animals exhibited reduced beta power compared to baseline
(p = 0.011) and an increased in fast gamma power (p = 0.008,
Figures 3F,G).
Temporal Effects of GSK-3 Inhibition on
HIP–PL Coherence
Oscillatory coherence between HIP and PL in vehicle-treated rats
and following GSK-3 inhibition was next examined (Figure 4). In
vehicle-treated rats (Figure 4A) the repeated measures ANOVA
revealed an Injection effect for all frequencies except delta [theta:
F(2,22) = 5.3, p = 0.016; beta: F(2,22) = 3.6, p = 0.049; slow
gamma: F(2,22) = 8.5, p = 0.002; fast gamma: F(2,22) = 13.9,
p = 0.0001]. At the completion of the 5 days of water maze
testing significant decreases in HIP–PL gamma coherence were
observed for all frequencies compared to baseline (Figure 4A).
Acute or repeated administration of SB 216763 increased
HIP–PL coherence in the delta, theta and slow gamma bands
(Figure 4B) [Injection Effects, delta: F(2,22) = 4.8, p = 0.018;
theta: F(2,22) = 3.5, p = 0.048; slow gamma: F(2,22) = 3.5,
p = 0.048]. Repeated, but not acute, lithium enhanced theta
band power compared to baseline with no effects on the other
frequencies (Figure 4C) [Injection Effects, theta: F(2,30) = 34.7,
p= 0.0001].
Frontiers in Aging Neuroscience | www.frontiersin.org 5 January 2018 | Volume 9 | Article 434
fnagi-09-00434 January 10, 2018 Time: 16:54 # 6
Nguyen et al. GSK-3 Effects on Neuronal Network Activity
FIGURE 2 | Temporal effects of GSK-3 inhibition on hippocampus (HIP) oscillations. (A) Electrode placements in HIP from each of the three treatment groups. (B,C)
Power spectrums and quantification showing no deviations from baseline in HIP oscillatory power with vehicle administration. (D) Repeated GSK-3 inhibition by SB
216763 (2.5 mg/kg) induced a theta spike in HIP at approximately 10 Hz (red arrow) and induced an overall increased in theta power in this region. (E) Quantification
of the HIP power spectrum at each frequency with SB 216763 treatment following water maze training on days 1 and 5, and at baseline. (F,G) Repeated lithium
(100 mg/kg) induced a 10 Hz theta spike (red arrow) but did not induce an overall increase in theta power (4–12 Hz). Reduced slow and fast gamma powers were
evident after acute treatment. N = 8 rats/group with 1–2 recordings/region/rat. Curves represent group means following acute (red) and repeated (blue) drug
administration. Bars represent means ± SEM and are expressed as percent of baseline. ∗p < 0.05 compared to baseline, paired Student’s t-test.
Effects of Direct GSK-3 Inhibition versus
Lithium on HIP and PL Oscillations and
Coherence
In addition to evaluating temporal changes in neural oscillatory
power and coherence following drug treatment (within subjects
comparisons), between group comparisons were also performed
(Figures 5, 6). In both HIP and PL, spectral power did
not differ between groups prior to drug administration, nor
did HIP–PL oscillatory coherence (Supplementary Figure S1).
After a single injection of vehicle, SB 216763 or lithium,
ANOVA analysis of spectral power revealed a significant effect
of Drug in the beta, slow and fast gamma bands for HIP
(Figures 6A,B) [beta: F(2,25) = 6.2, p = 0.005; slow gamma:
F(2,25) = 15.8, p = 0.0001; fast gamma: F(2,25) = 8.5,
p = 0.001]. Acute administration of either SB 216763 or
lithium induced robust decreases in both slow and fast gamma
compared to vehicle (Figures 5A,B). With repeated drug
treatment significant Drug effects were evident in the theta
and fast gamma bands [theta: F(2,25) = 3.5, p = 0.041; slow
gamma: F(2,25) = 3.5, p = 0.039]. Compared to vehicle, only
SB 216763 exhibited increased overall theta power following
repeated treatment (Figures 5C,D). However, a significant
increase in theta power (9–11 Hz) was evident following either
SB 216763 (p = 0.005) or lithium (p = 0.028, Figures 5C,D)
compared to the controls [ANOVA: theta (9–11), F(2,25) = 6.9,
p= 0.003].
In PL no significant effects were evident following acute
drug administration (Figures 5E,F), with significant theta and
fast gamma Drug effects following repeated treatment [theta:
F(2,25)= 5.4, p= 0.008; fast gamma: F(2,25)= 10.2, p= 0.0001].
Repeated SB 216763 or lithium each increased theta power
compared to vehicle (p = 0.020 and p = 0.028, respectively,
Figures 5G,H). Repeated lithium also increased fast gamma
power in PL compared to vehicle-treated rats (p= 0.012).
Frontiers in Aging Neuroscience | www.frontiersin.org 6 January 2018 | Volume 9 | Article 434
fnagi-09-00434 January 10, 2018 Time: 16:54 # 7
Nguyen et al. GSK-3 Effects on Neuronal Network Activity
FIGURE 3 | Temporal effects of GSK-3 inhibition on prelimbic cortex (PL) oscillations. (A) Electrode placements in PL from each of the three treatment groups. (B,C)
Power spectrums and quantification showing no deviations from baseline in PL oscillatory power with vehicle administration. (D) Compared to baseline repeated SB
216763 (2.5 mg/kg) increased theta power in PL. Acute or repeated SB 216763 suppressed slow gamma power. (E) Quantification of the PL power spectrum at
each frequency at baseline and following SB 216763 administration on days 1 and 5. (F,G) Changes in the power spectrum and quantification following acute or
repeated lithium (100 mg/kg) treatment. N = 8 rats/group with 1–2 recordings/region/rat. Curves represent group means following acute (red) and repeated (blue)
drug administration. Bars represent absolute value means ± SEM and are expressed as percent of baseline. ∗p < 0.05, ∗∗p < 0.01 compared to baseline, paired
Student’s t-test.
A comparison of HIP–PL oscillatory coherence (Figure 6)
between drug treatments revealed significant Drug effects at all
frequencies [delta: F(2,25) = 8.3, p = 0.001; theta: F(2,25) = 2.9,
p = 0.049; beta: F(2,25) = 4.0, p = 0.024; slow gamma:
F(2,25) = 3.9, p = 0.024; slow gamma: F(2,25) = 3.4, p = 0.035].
Compared to vehicle, direct inhibition of GSK-3 by SB 216763
increased coherence at all frequencies except delta following
repeated, but not acute treatment (Figure 6). Conversely,
lithium suppressed HIP–PL delta and theta coherence with acute
treatment, with reduced delta coherence with repeated treatment.
DISCUSSION
A pivotal role for GSK-3 in the regulation of learning and
memory is widely accepted. Yet, except for its involvement in
tau hyperphosphorylation and NFT formation in AD, little is
known regarding the mechanisms by which GSK-3 regulates
cognitive function. In the present study, we showed in rats
that systemic inhibition of GSK-3 activity had direct effects on
neuronal oscillatory activity in HIP and PL, and further, that
direct GSK-3 inhibition induced oscillatory changes that were
distinct from the non-selective GSK-3 inhibitor lithium. Selective
inhibition of GSK-3 by SB 216763 significantly improved spatial
memory and altered the animals’ learning strategy, increasing
goal-directed exploratory behavior within the center of the maze.
At the completion of behavioral testing, analysis of LFPs revealed
there was a 10 Hz theta frequency spike in HIP following either SB
216763 or lithium. However, whereas selective GSK-3 inhibition
increased overall theta power in both HIP and PL, lithium
induced a theta power increase selectively in PL coincident with
an increase in fast gamma power. Furthermore, whereas repeated
SB 216763 increased HIP–PL coherence across all frequencies,
lithium suppressed delta coherence, with no effect at the other
frequencies.
Preclinical studies in animal models of disease have provided
promising evidence of cognitive improvement as a result of
treatment with GSK-3 inhibitors, with beneficial effects of GSK-3
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FIGURE 4 | Temporal effect of GSK-3 inhibition on HIP-PL coherence. (A) Repeated vehicle administration suppressed HIP–PL coherence. (B) Acute or repeated
SB 216763 (2.5 mg/kg) increased theta coherence compared baseline, with increased delta and low gamma coherence with repeated treatment. (C) Repeated
lithium (100 mg/kg) increased theta power compared to baseline. N = 8 rats, 1–2 recordings/region/rat. Curves represent group means following acute (red) and
repeated (blue) drug administration. Bars represent means ± SEM and are expressed as percent of baseline. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 compared to
baseline, paired Student’s t-test.
inhibition, either by lithium or selective inhibitors, having been
demonstrated in model systems of schizophrenia (Beaulieu et al.,
2004; Chan et al., 2012; Lipina et al., 2013; Maksimovic et al.,
2014), Fragile-X syndrome (Yuskaitis et al., 2010; Guo et al., 2012;
Franklin et al., 2014; Pardo et al., 2017) as well as traumatic
brain injury (Yu et al., 2012a,b). In addition, the large number
of reports that have focused on AD, as a result of the known
role of GSK-3 in AD neuropathology, are also positive showing
significant improvements not only in cognitive performance but
also in AD-related pathologies (Hu et al., 2009; Sereno et al., 2009;
Gong et al., 2011; Onishi et al., 2011; Zhang et al., 2011; Avrahami
et al., 2013; Noh et al., 2013; Nunes et al., 2015). In humans,
however, the clinical efficacy of these compounds remains less
clear, partly because of a lack of studies evaluating the impact
of selective GSK-3 inhibitors on cognition and partly due to the
large number of conflicting reports from studies evaluating the
therapeutic effects of lithium. For example, clinical studies for
the most part have demonstrated beneficial effects of lithium in
improving cognition or preventing further cognitive decline in
AD (Nunes et al., 2013; Matsunaga et al., 2015; Forlenza et al.,
2016). Yet, positive effects (Letendre et al., 2006), or no effect
(Schifitto et al., 2009; Decloedt et al., 2016) of lithium treatment
have been shown for HIV-associated cognitive decline, and in
bipolar disorder the findings are even more conflicting with
reports showing positive effects (Daglas et al., 2016), little to no
effects (Joffe et al., 1988; Bourne et al., 2013; Pfennig et al., 2014),
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FIGURE 5 | Effect of GSK-3 inhibition on HIP and PL oscillations. (A,B) Acute administration of SB 216763 (2.5 mg/kg) or lithium (100 mg/kg) reduced slow and fast
gamma power in HIP. (C) Repeated SB 216763 or lithium induced a theta spike at approximately 10 Hz. (D) Quantification of the power spectrum showing
increased overall theta power following SB 216763, but not lithium, compared to vehicle. (E,F) Acute SB 216763 or lithium did not alter PL oscillatory power.
(G,H) Repeated SB 216763 or lithium increased theta power in PL compared to vehicle-treated rats. Lithium also induced an increase in fast gamma power. N = 8
rats/group with 1–2 recordings/region/rat. Curves represent group means following acute (red) and repeated (blue) drug administration. Bars represent
means ± SEM. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 compared to vehicle, Bonferroni post hoc test.
or negative effects (Shaw et al., 1987; Monks et al., 2004; Senturk
et al., 2007) of treatment on cognitive function.
In contrast to the numerous studies that have evaluated the
effects of GSK-3 inhibition on cognition in neuropsychiatric
and neurodegenerative disease, fewer studies have examined the
effects of these compounds in healthy animals and humans.
In animals, conflicting results due to differing dosing and
treatment regimens make their impact on cognitive performance
more difficult to define. For example, in mice acute treatment
with the GSK-3 inhibitors TDZD-8 or VP0.7, or repeated
treatment with SB 216763 every other day for 2 weeks, did
not alter spatial learning (Guo et al., 2012; Franklin et al.,
2014) whereas treatment with the dual phosphodiesterase-7
and GSK-3 inhibitor VP1.15 improved performance in the
spatial object recognition test, the Y-maze task, and cued fear
memory (Lipina et al., 2013). In rats, inhibition of GSK-
3 following icv infusion of SB 216763 (20 ng/µl) did not
affect performance in the Morris water maze (Tian et al.,
2012), in contrast to the present findings which clearly showed
a cognitive enhancing effect of the drug when repeatedly
administered systemically at a dose of 2.5 mg/kg. Similar
discrepancies have been reported with lithium with one study
showing reduced spatial memory with intra-HIP administration
(Parsaei et al., 2016), other studies showing enhanced cognitive
performance with lithium treatment (Nocjar et al., 2007; Tsaltas
et al., 2007), and other reports showing little or no effect of
this compound in cognitive tasks (Vasconcellos et al., 2003;
de Vasconcellos et al., 2005; Watase et al., 2007; Dai et al., 2012;
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FIGURE 6 | Effect of GSK-3 inhibition on HIP–PL coherence in rats. (A) No effect of acute SB 216763 (2.5 mg/kg) on HIP–PL coherence whereas lithium
(100 mg/kg) suppressed delta and theta coherence. (B) Repeated SB 216763 increased HIP–PL coherence at all frequencies except delta. Lithium selectively
suppressed delta coherence. N = 8 rats/group with 1–2 recordings/region/rat. Curves represent group means following acute (red) and repeated (blue) drug
administration. Bars represent means ± SEM. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 compared to vehicle, Bonferroni post hoc test.
Contestabile et al., 2013; King and Jope, 2013). The findings
reported herein also showed a lack of effect of lithium in
spatial learning using a dose previously shown to increase Akt
activity (Zheng et al., 2013), a kinase known to phosphorylate
and inhibit GSK-3, although positive trends were observed in
some of the parameters evaluated. This lack of an effect of
lithium on cognitive performance has also been consistently
demonstrated in healthy humans, with some studies also showing
lithium-induced mild impairments in various cognitive domains
(Weingartner et al., 1985; Linnoila et al., 1986; Stip et al., 2000;
Wingo et al., 2009).
The large number of conflicting reports evaluating the effects
of lithium on cognition in both healthy and diseased states
indicate that any of the observed therapeutic effects of lithium
on cognition may not only reflect a combination of different
dosing regimens but may be dependent on the disease under
investigation. Although one mechanism of action of lithium
is the inhibition of GSK-3, it is necessary to keep in mind
that lithium has an array of biological substrates which would
undoubtedly contribute to the drug’s effects. It is therefore logical
that the functional effects of lithium could induce differing
behavioral responses a result of interactions with the various
neuropathologies under study. Lithium has been shown to inhibit
other enzymes such as IMPAs (Berridge et al., 1989), BPNT1
(Spiegelberg et al., 2005), and cyclooxygenase (COX) (Klein and
Melton, 1996; Stambolic et al., 1996). Therefore, even if lithium
could have positive effects on cognitive processes through GSK-3
inhibition, some of these effects may be offset through its actions
at other targets.
Although further research is required to determine the
precise mechanisms underlying GSK-3 effects on cognition, one
possible mediator is the NMDA receptor. In primary cortical
pyramidal neurons or cortical slices GSK-3 was shown to
phosphorylate NR2B-containing NMDA receptors, resulting in
increased receptor internalization, and leading to a reduction
in synaptic current (Chen et al., 2007; Li et al., 2009). Another
result of increased GSK-3 activity is the phosphorylation of
β-catenin and its subsequent degradation, leading to inhibition
of GluN2B gene transcription (Li et al., 2009). Reports indicate
that increased GSK-3 activity in might predispose synapses to
LTD, suppress long-term potentiation (LTP), and/or shift the
threshold of LTP induction through alteration of AMPA and/or
NMDA receptor trafficking (Peineau et al., 2007, 2008; Bradley
et al., 2012). Interestingly, it has been proposed that inositol
depletion by lithium may disrupt LTP through its effects at
IMPAs (Berridge et al., 1989), a hypothesis supported by evidence
showing a lithium-induced reduction of cellular levels of IP3
(Berridge et al., 1989; Sarkar et al., 2005), a process critical
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to cytosolic calcium influx and LTP. In addition, inactivation
of NMDA receptors of the dorsal hippocampus were proposed
to be involved in lithium-induced spatial learning impairment
(Parsaei et al., 2016). On the other hand, COX inhibitors have
been demonstrated to have positive effects on HIP and cortex-
related cognitive functioning in mice (Syed et al., 2015), but
inhibit spatial memory retention in rats (Sharifzadeh et al., 2005)
suggesting that the interplay between these different lithium
targets are complex and make the resulting behavioral outcomes
difficult to predict.
One notable similarity between SB 216763 and lithium
was that administration of either drug increased HIP and PL
theta oscillations, although only SB 216763 increased HIP–PL
theta coherence. Theta rhythms are critically associated with
movement (Vanderwolf, 1969), are present during behaviors
associated with salient stimuli (Tesche and Karhu, 1999), and
have been linked to behaviors related to decision-making
processes, such as spatial memory in rodents (Jones and Wilson,
2005) or working memory in humans (Kahana et al., 1999; Tesche
and Karhu, 1999; Raghavachari et al., 2001). Both repeated SB
216763 or lithium induced a 10 Hz HIP theta spike, although
an overall increase in theta power was evident only following SB
216763 administration. The theta rhythm in HIP specifically is
known to play a pivotal role in learning and memory function
and to impact directly on performance in specific cognitive
tasks (see reviews, Harris and Gordon, 2015; Korotkova et al.,
2017). For example, disruption of the HIP theta rhythm in
rats suppressed initial learning in the water maze (McNaughton
et al., 2006), and reduced both working and reference memory
performance in a continuous conditional discrimination task
(Givens and Olton, 1994). Repeated SB 216763 and lithium
administration were also shown to result in increased theta
oscillatory activity in PL. Although less is known regarding
the role of PFC theta in learning and memory, in human
patients mid-frontal cortical theta activity was reported to serve
as temporal context for the coordination of networks during
learning, specifically within the medial PFC (Mas-Herrero and
Marco-Pallares, 2016), and was also suggested to be integral
in the regulation of ‘cognitive control’ (Cavanagh and Frank,
2014). SB 216763 increased HIP-PL theta coherence, although a
similar change was not observed with lithium treatment. Studies
have demonstrated links between HIP–PFC theta coupling
with performance in a variety of spatial memory tasks (Jones
and Wilson, 2005; Benchenane et al., 2010; Hyman et al.,
2010).
A note on methodology: a caveat of the present study was
that recordings were taken following water maze training with
the rats anesthetized at the time of recording. The study was
designed in this manner for two reasons. Firstly, the numerous
conflicting reports in evaluating the impact of GSK-3 inhibition
on learning and memory in healthy animals indicated we utilize
a test in which the animals would be very motivated to complete
and at the same time minimize variables that would contribute
to alterations in neuronal oscillations, such as food restriction.
In line with this, anesthetizing the animals would minimize
contributions of neuronal oscillatory changes resulting from
stress, fatigue, and consequently movement and alertness, and
thus the focus would be predominantly on the exploration of
direct drug effects. Clearly further characterization of GSK-3
effects on oscillations and their correlation to behavioral output
would require recordings to occur in awake freely behaving
animals. In addition, it is important to keep in mind that
normalization of the spectra conserves the total power across
the entire spectrum. Thus, what is represented are not changes
in absolute values, but rather changes in the shape of the curve
following drug treatment. Yet, despite these limitations, these
findings lay the groundwork for a potential new avenue of
research evaluating in depth the relationship between GSK-3
activity and neuronal oscillations in specific regions of the brain
and the importance of this relationship in central nervous system
disorders.
CONCLUSION
The present findings point to a previously unknown role
for GSK-3 in the regulation of neuronal HIP and PL theta
oscillations in brain that could provide a lead into what could
happen if GSK-3 activity became abnormally increased in
a pathophysiologic state. Although conflicting reports of the
therapeutic effects of lithium on cognition currently raise caution
as to the therapeutic benefit of this drug in cognitive dysfunction
disorders, furthering our understanding of the exact mechanisms
that underlie the disparate effects of lithium on learning and
memory would clearly be beneficial given its widespread use
in the treatment of neuropsychiatric disorders. This idea is
strengthened by the present findings which showed that direct
inhibition of GSK-3 improved spatial memory and enhanced
theta oscillations in both HIP and PL, two regions integral to
cognitive function.
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